BIOMAT Database Logo BIOMAT Database Logo

Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension. 1998

G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D001944 Breath Tests Any tests done on exhaled air. Breathalyzer Tests,Breath Test,Breathalyzer Test,Test, Breath,Test, Breathalyzer,Tests, Breath,Tests, Breathalyzer
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D016285 Iloprost An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation. Ciloprost,Ventavis,ZK-36374,ZK 36374,ZK36374

Related Publications

G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis.
August 1998, Lancet (London, England),
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis.
December 2016, Pulmonary circulation,
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension.
December 1997, Thorax,
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement.
August 2007, Chest,
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension.
February 2004, Chest,
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy.
August 2005, American journal of respiratory and critical care medicine,
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease.
January 2017, Canadian respiratory journal,
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Increased nitric oxide in exhaled air in patients with systemic sclerosis.
January 1998, Clinical and experimental rheumatology,
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Nitric Oxide in Systemic and Pulmonary Hypertension.
January 1997, Journal of biomedical science,
G Rolla, and P Colagrande, and L Brussino, and C Bucca, and M T Bertero, and F Caligaris-Cappio
Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension.
January 2018, BioMed research international,
Copied contents to your clipboard!